Pre-Test Immunotherapy in the Management of Cutaneous Melanoma: Multidisciplinary Treatment Strategies and Adverse Event Mitigation Pre-Test Which of the following is the most common histological subtype of melanoma, presenting as asymmetric lesions with irregular or indistinct borders, displaying various shades of brown, black, pink, or other colors, and accounting for more than 70% of cases? Acral lentiginous melanoma Lentigo maligna Nodular melanoma Superficial spreading melanoma Unsure In the recent phase 2 SWOG study of patients with resectable stage III or IV melanoma, event-free survival was significantly longer among those who received _______ both before and after surgery than among those who received it in the adjuvant setting alone. Ipilimumab plus nivolumab Nivolumab Pembrolizumab Relatlimab Unsure Approximately what percentage of patients treated with ICIs develop cutaneous/dermatologic immune-related adverse events (irAEs), requiring early recognition and appropriate management to prevent dose modifications and discontinuation of ICIs? 10-30% 20-40% 30-50% 40-60% Unsure How confident are you in your ability to implement multidisciplinary strategies to monitor for, identify, and mitigate irAEs among patients receiving ICI treatment for advanced melanoma? Very confident Confident Somewhat confident Not very confident Not at all confident
